TAF2

Across TCGA pan-cancer cohorts, TAF2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of TAF2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where TAF2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TAF2 is over-expressed in tumor.

HNSC, LSCC, and LUAD are the cancer types where TAF2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TAF2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+0.363	<.001	11	view →
LSCC	Male	All	+0.312	<.001	8	view →
LUAD	Male	All	+0.165	<.001	7	view →
CCRCC	Male	III,IV	+0.097	.016	3	view →
PDAC	Female	III,IV	+0.564	.027	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

TAF2–HNSC

Open the HNSC breakdown →